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Introduction
Thenovelcoronavirus2019(COVID-19) isbeingrapidlydiffused
worldwide from China to Europe and now in United States,
so creating serious medical and social issue to contain its
potentially dangerous complications. COVID-19 is, in fact, com-
plicated by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), which is responsible for a high number of
patients needing mechanical ventilation or intensive care units
(ICU) treatment and for the elevated mortality risk. However,
lung damage is not the only reason for the high death risk as
other organs such as heart and kidney may be seriously
damaged and favor poor survival. This entails that SARS-CoV-
2 is amultiorgandiseasewithmechanismssuchas, for example,
systemic inflammation which may precipitate organ failure.
A link between COVID-19 and multiorgan failure may be
dependent on the fact that almost all patients hospitalized
for COVID-19 disease are complicated by pneumonia, which
is known to be associated with systemic inflammation and
thrombotic-related events such as myocardial infarction (MI)
and ischemic stroke.1,2 Accordingly, previous studies reported
that patients with pneumonia display changes of clotting and
platelet activation,3,4 which occur during the early phase of
disease and may precipitate systemic or local thrombosis. It is
arguable, therefore, that SARS-CoV-2 patients may experience
thrombotic events in coronary and cerebral trees or in other
circulatory districts including lung and kidney. Clinical data so
far reported are suggestive of vascular complications occurring
in the coronary circulation while the involvement of other
districts is still unclear.5–7 Conversely, there are many studies
reporting that the behavior of clotting variables and platelet
count in COVID-19 patients is suggestive of a hypercoagulation
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state. As clinical presentation and complications of COVID-19 is
wide, in this review we sought to determine if changes of
clotting variables are dependent on the severity of the disease.
To this purpose,we performed a systematic reviewof the SARS-
CoV-2 literature reporting measures of clotting activation to
assess if changes are detectable in this setting and their rela-
tionshipwithclinical severity. Thus, clotting variableshavebeen
examined in patients divided according to the severity of SARS-
CoV-2. Furthermore, we discussed the biologic plausibility of
the thrombotic risk in SARS-CoV-2 and the potential use of an
antithrombotic treatment.
Eligibility Criteria
Types of studies: clinical studies in patients with COVID-19
infection in humans that assessed the following laboratory
parameters: d-dimer, platelet counts, prothrombin time,
activated partial thromboplastin time, alanine aminotrans-
ferase, and aspartate aminotransferase. The studies included
in this systematic review had to show COVID-19 infection
with severe disease and control group.
No publication date or publication status restrictions
were imposed. Only publicationswritten in English language
were included in this systematic review.
Information Sources
The studies were identified by searching electronic data-
bases. This searchwas applied to PubMed, ISIWeb of Science,
SCOPUS, and Cochrane database. The last search was run on
March 28, 2020. Reference lists of all studies included in the
present systematic review were screened for potential addi-
tional eligible studies.
Search
Two investigators (D.P. and L.L.) independently searched in the
electronic databases combining the following text terms and
MeSH terms: ((“coronavirus” [MeSH Terms] OR “coronavirus”
[All Fields]) AND (“COVID-19” [All Fields] OR “COVID-2019”
[All Fields]OR “severe acute respiratory syndromecoronavirus
2”[Supplementary Concept] OR “severe acute respiratory syn-
drome coronavirus 2”[All Fields] OR “2019-nCoV”[All Fields]
OR “SARS-CoV-2”[All Fields] OR “2019nCoV”[All Fields] OR
((“Wuhan”[All Fields] AND (“coronavirus”[MeSH Terms] OR
“coronavirus”[All Fields])) AND (2019/12[PDAT] OR 2020
[PDAT])))) AND “humans”[MeSH Terms].
Study Selection
Two authors (L.L. and D.P.) independently reviewed titles and
abstracts generated by search. Studies were excluded if the
title and/or abstract showed that the papers did not meet the
selection criteria of our systematic review. For potentially
eligible studies or if the relevance of an article could not be
excluded with certitude, we procured the full text. Disagree-
ments were resolved by discussion between L.L. and D.P.; if
no agreement reached, a third author (F.V.) decided.
Studies not including a control group and animal studies
were excluded. Case reports, editorials, commentaries, let-
ters, review articles, and guidelines were also excluded from
the analysis. ►Fig. 1 reports the PRISMA diagram.
Clotting Changes in Coronavirus 2019
We analyzed some variables of variable of clotting and fibri-
nolysis activation along with platelet count in all COVID-19
population (►Table 1) and in patients according to disease
severity (►Table 2). The latterwasdefined as acute respiratory
distress syndrome (ARDS), need ofmechanical ventilation/ICU
treatment, nonsurvivor patients, or severe pneumonia.8 Our
analysis considered globally nine reports.9–17
D-Dimer
D-dimersvalueswere reported inall (9–12and14–17)butone
study13 and definition of increased values in six out of eight
studies.9,10,12,15–17Among the six studies, one17 reported only
the percentage of patients with increased values of D-dimer
while the other reported also the absolute values. The per-
centage of patients with elevated D-dimer was almost wide
with high values ranging from 14 to 46%. Analysis of D-dimer
according to disease severity was reported in six studies
(►Table 2), and all consistently showed increased values of
D-dimer in patients with severe versus nonsevere disease;
significance was shown in all but two studies.14,17 These data
are in accordance with a recent meta-analysis showing en-
hanced D-dimer according to disease severity.18
Platelet Count
Platelet count data were extrapolated from seven stud-
ies,9–13,16,17 of which six9–12,16,17 reported changes in
terms of low platelet count. Reduced platelet count was
detected from 5 to 18% of the entire population; platelet
count was roughly around 100,000 µL and in some cases
below this value. The impact of disease severity on platelet
count was reported in five studies11–13,16,17 with a signifi-
cant reduction in nonsurvivors compared with survivors;
however, a trend toward a reduction of platelet count in
patients with severe disease was reported in all studies,
which is in accordance with a previous report showing that
thrombocytopenia is more frequent in patients with severe
disease.19
Prothrombin Time
We extrapolated data from 8 (9–16) studies, but only
59,10,12,15,16 reported changes in terms of PT prolongation,
which was detected from 2 to 11% of the entire population.
The rate of PT prolongation was not reported in all, but one
study9 where a small prolongation can be appreciated.
Conversely, analysis of PT according to disease severity
was done in six studies,11–16 where PT was reported be
longer in patients with severe compared with those without
severe disease; prolongation of PT was more evident in
nonsurvivors with values exceeding 15 to 16 seconds.
Activated Partial Thromboplastin Time
We extrapolated data from six studies (9–11 and 14–16) but
only three9,10,16 reported changes in terms of aPTT prolonga-
tion,whichwasdetected from6to26%of theentirepopulation.
The rate of aPTT prolongationwas unclear with only one study
showing a modest increase. Five studies reported the behavior
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of aPTT according to the disease severity.11,12,14–16 Data are
difficult to interpret asprolongation aswell as shortening aPTT
were reported in patients with severe versus nonsevere dis-
ease; prolongation of aPTT seemed to occur in nonsurvivors,
but data need to be confirmed.
Liver Failure in Coronavirus 2019
As the prolongation of PT and aPTT could be dependent upon
impaired liverbiosynthesis and/orcoagulopathy,20weanalyzed
if COVID-19 patients showed changes in transaminases.
We found six studies9–12,16,17 reporting alanine transami-
nase (ALT) serum values: changes in terms of values exceeding
normal rangewas reported in four,9,10,12,17which showed ALT
increase in 12 to 31% of patients. The rate of ALT increase was
unclear as only one study showed absolute values, whichwere
approximately twofold thenormal range. Four studies11,12,16,17
reported ALTvalues according to the disease severity, and only
two showed a modest increase in case of ARDS or poor
survival.12,16
We found five studies9–11,16,17 reporting aspartate amino-
transferase (AST) serum values; changes in terms of values
exceeding normal range were reported in four,9–11,17 which
showed AST increase in 18 to 62% of the entire population and
in one study reporting absolute values, the AST increase was
modest. Three studies11,16,17 reported ASTvalues according to
the disease severity and only two11,16 showed a modest but
significant increase(►Table 2). Together, these data show that
in COVID-19 liver failure is almost modest and, thereby, does
not seem to have an impact on clotting changes.
Biological Plausibility of Hypercoagulation
in Coronavirus 2019
Hospitalized patients affected by COVID-19 are frequently
complicated by serious pneumonia, which may occur, from
roughly 80 to 100% of cases.11,21,22 Considering that respirato-
ry tract infections are associated with an increased risk of
vascular disease, including artery and venous thrombosis, it is
not surprising that SARS-CoV-2 may be complicated by clot-
ting changes that ultimately lead to thrombosis. Among artery
thrombosis complications patients with pneumonia may ex-
perienceMI in approximately 10% of cases, and less frequently,
ischemic stroke.3 In SARS-CoV-2 patients, detailed description
of cardiovascular complications is still lacking even if in some
reports it is possible to appreciate data indicating the occur-
rence of myocardial damage as depicted by enhanced levels of
troponin associated or less with EKG changes compatiblewith
MI.6,7 Conversely, no data have been so far reported regarding
Fig. 1 Hypothetic mechanisms accounting for hypercoagulation in severe acute respiratory syndrome coronavirus 2 patients.
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Table 2 Coagulation and liver parameters in patients with coronavirus 2019 infection according to severity of the disease
Study (year) Number of patients Severe Nonsevere p-Value
D-dimer
Huang et al11 (2020) 41 (13 ICU, 28 no ICU) 2.4 (0.6–14.4) 0.5 (0.3–0.8) p¼ 0.0042
Zhou et al12 (2020) 191 (54 nonsurvivors, 137 survivors) 5.2 (1.5–21.1)c 0.6 (0.3–1.0)c p< 0.0001
>1 µg/L¼ 44 (81%) >1 µg/L¼ 28/118 (24%) p< 0.0001
Han et al14 (2020) 94 (49 ordinary, 35 severe, 10 critical) Severe: 19.11 35.48
Critical: 20.04 32.39
2.14 2.88 n.r.
Tang et al15 (2020) 183 (21 nonsurvivors, 162 survivors) 2.12 (0.77–5.27) 0.61 (0.35–1.29) p< 0.001
Wu et al16,a (2020) 117 (no ARDS, 84 ARDS) 1.16 (0.46–5.37) 0.52 (0.33–0.93) p< 0.001
40 ARDS alive, 44 ARDS died 3.95 (1.15–10.96) 0.49 (0.31–1.18) p¼ 0.001
Guan et al17 (2020) 1,099 COVID-19 patients (926 non-
severe vs. 173 severe)
65/109 (59.6)> 0.5 mg/L 195/451 (43.2) mg/L n.r.
Platelet count
Huang et al11 (2020) 41 (13 ICU, 28 no ICU) 196 (165–263) 149 (131–263) p¼ 0.450
<100¼ 1/13 (8%) <100¼ 1/27 (4%) p¼ 0.450
Zhou et al12 (2020) 191 (54 nonsurvivors, 137 survivors) 165.5 (107.0–229.0) 220.0 (168.0–271.0) p< 0.0001
<100¼ 11 (20%) <100¼ 2 (1%) p< 0.0001
Yang et al13 (2020) 52 (32 nonsurvivors, 20 survivors) 191 (63) 164 (74) n.r.
Wu et al16 (2020) 117 (no ARDS, 84 ARDS) 187.00 (124.50–252.50) 178.00 (140.00–239.50) 0.730
40 ARDS alive, 44 ARDS died 162.00 (110.50–231.00) 204.00 (137.25–262.75) 0.100
Guan et al17 (2020) 1,099 COVID-19 patients (926 non-
severe vs. 173 severe)
137,500
(99,000–179,500)
172,000
(139,000–212,000)
n.r.
<150,000 per mm3 90/156 (57.7) 225/713 (31.6) n.r.
Prothrombin time
Huang et al11 41 (13 ICU, 28 no ICU) 12.2 (11.2–13.4) 10.7 (9.8–12.1) p¼ 0.012
Zhou et al12 (2020) 191 (54 nonsurvivors, 137 survivors) 12.1 (11.2–13.7) 11.4 (10.4–12.6) p¼ 0.0004
16 seconds¼ 7 (13%) 16 seconds¼ 4/128 (3%) p¼ 0.016
Yang et al13 52 (32 nonsurvivors, 20 survivors) 12.9 (2.9) 10.9 (2.7) n.r.
Han et al14 (2020) 94 (49 ordinary, 35 severe, 10 critical) Severe: 12.65 1.13
Critical: 12.80 0.87
12.20 0.88 n.r.
Tang et al15 (2020) 183 (21 nonsurvivors, 162 survivors) 15.5 (14.4–16.3) 13.6 (13.0–14.3) p< 0.001
Wu et al16 (2020) 117 no ARDS, 84 ARDS 11.70 (11.10–12.45) 10.60 (10.10–11.50) p< 0.001
40 ARDS alive, 44 ARDS died 11.60 (11.10–12.45) 11.75 (10.95–12.45) p¼ 0.870
Activated partial thromboplastin time
Huang et al11 41 (13 ICU, 28 no ICU) 26.2 (22.5–33.9) 27.7 (24.8–34.1) p¼ 0.570
Zhou et al12 (2020) 191 (54 nonsurvivors, 137 survivors) 27 (50%)b 10 (7%)b p< 0.0001
Han et al14 (2020) 94 (49 ordinary, 35 severe, 10 critical) Severe: 29.53 3.48
Critical: 29.41 1.68
28.56 2.66 n.r.
Tang et al15 (2020) 183 (21 nonsurvivors, 162 survivors) 44.8 (40.2–51.0) 41.2 (36.9–44.0) p¼ 0.096
Wu et al16 (2020) 117 (no ARDS, 84 ARDS) 26.00 (22.55–35.00) 29.75 (25.55–32.85) p¼ 0.130
40 ARDS alive, 44 ARDS died 24.10 (22.25–28.35) 29.60 (24.00–35.75) p¼ 0.040
ALT
Huang et al11 (2020) 41 (13 ICU, 28 no ICU) 49.0 (29.0–115.0) 27.0 (19.5–40.0) 0.038
Zhou et al12 (2020) 191 (54 nonsurvivors, 137 survivors) 40.0 (24.0–51.0) 27.0 (15.0–40.0) 0.005
>40 26 (48%) 33/135 (24%) 0.0015
Wu et al16 (2020)a 117 (no ARDS, 84 ARDS) 35.00 (21.50–52.50) 27.00 (18.00–41.50) 0.01
40 ARDS alive, 44 ARDS died 39.00 (20.50–52.50) 35.00 (23.25–55.25) 0.71
Guan et al17 (2020) 1,099 COVID-19 patients
(926 nonsevere vs. 173 severe)
38/135 (28.1)> 40 U/L 120/606 (19.8)> 40 U/L n.r.
(Continued)
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deep venous thrombosis. Systemic coagulation abnormalities,
including clotting activation and inhibition of anticoagulant
factors, have been observed not only in sepsis but also in
pneumonia.
At this last regard, we have previously reported that
pneumonia may be associated with clotting activation as
well as lowering of natural anticoagulants. Thus, we found
enhanced levels of the prothrombin fragment F1þ 2, which
is a marker of thrombin generation, along with impaired
activation of the anticoagulant Protein C. These changes
occurred during the acute phase of the disease and tended
to normalize at the discharge.4
Platelet activation has been investigated bymeasuring the
soluble levels of CD40L and P-selectin, which were both
elevated during the acute phase of pneumonia, along with
an overproduction of platelet thromboxane (Tx) B223; of
note, platelet TxB2 was independently associated with the
occurrence of MI. Finally, we observed that patients with
pneumonia display impaired artery dilatation, which is
detectable during the acute phase of the disease and improve
at discharge.24
The mechanism accounting for these changes is not clear,
but it is intriguing that Nox2, which is the most important
enzyme generating reactive oxidant species (ROS), is over-
activated in patients with pneumonia.25 Thus, Nox2 is impli-
cated in artery dilatation and platelet activation by
inactivating nitric oxide or enhancing platelet eicosanoid
production; experimental model of platelet-related throm-
bosis provided support to the role of Nox2 as in Nox2 animal
knockout thrombus growth is prevented.26,27
Thus, there are at least three changes occurring during the
acute phase of pneumonia, which may precipitate artery
and/or venous thrombosis (►Fig. 2). The mechanisms ac-
counting for clotting and vascular changes have not been
defined yet by systemic inflammation, including production
of reactive oxidant ROS might have a role. In this context,
there are growing bodyof experimental and clinical evidence
that Nox2-derived ROS are implicated in both clotting and
platelet activation, acting as intrasignaling pathway to pro-
mote thrombin generation and platelet aggregation or to
impair artery dilatation26,27 (►Fig. 2). Data regarding Nox2
in SARS-CoV-2 patients are still lacking but should be
Table 2 (Continued)
Study (year) Number of patients Severe Nonsevere p-Value
AST
Huang et al11 41 (13 ICU, 28 no ICU) 44.0 (30.0–70.0) 34.0 (24.0–40.5) 0.10
Wu et al16 (2020)a 117 (no ARDS, 84 ARDS) 38.00 (30.50–53.00) 30.00 (24.00–38.50) <0.001
40 ARDS alive, 44 ARDS died 37.00 (30.00–52.00) 38.50 (32.25–57.25) 0.21
Guan et al17 (2020) 1099 COVID-19 patients (926 nonse-
vere vs. 173 severe)
56/142 (39.4)> 40 U/L 112/615 (18.2)> 40 U/L n.r.
Abbreviations: ALT, alanine transaminase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; CI, confidence interval;
COVID-19, coronavirus 2019; ICU, intensive care unit; n.r., not reported.
aHazard ratio for progression to ARDS 1.03 (95% confidence interval: 1.01–1.04), p< 0.001; hazard ratio for progression to death 1.02 (95% CI: 1.01–
1.04), p¼ 0.002.
bNumbers refers to coagulopathy defined as a 3-second extension of prothrombin time or a 5-second extension of activated partial thromboplastin time.
cMultivariable odds ratio for in-hospital death for D-dimer >1 µg/L¼ 18.42 (95% CI: 2.64–128.55), p¼ 0.0033.
Fig. 2 Suggested algorithm for antithrombotic treatment in severe acute respiratory syndrome coronavirus 2 patients.
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investigated as experimental data provided evidence for a
role played by Nox2 upregulation in the systemic inflamma-
tion and pathogenicity elicited by several RNA viruses in-
cluding influenza virus.28
Data regarding clotting changes in SARS-CoV-2 are still
sparse and elusive. The only finding which could be consistent
with clotting activation is the increase of D-dimer; however,
which is not specific for clotting activation as it may also
increase as result of systemic proteolysis.29 There is also a
trend toward PT prolongation and low platelet count in
patients with severe disease, suggesting a role for coagulation
inprecipitatingpooroutcomes. Preliminarydata regarding the
relationship between elevated D-dimer and poor outcome
would be in favor of this hypothesis, but limited study meth-
odology precludes definite conclusions.12
Perspectives and Conclusion
The data so far reported are suggestive of low-grade intravas-
cular clotting activation, which is evident overall in patients
with severe disease. The findingmore consistent in support of
this hypothesis is the increase of D-dimer, which is almost
evident in patients with severe; in a small series of a retro-
spective study, D-dimer was associated with poor survival.16
Concerning PT, aPTT and platelet count data are more elusive
even if there is a trend for changes suggestive of a hyper-
coagulationstate in patients with severe disease. Thus, future
study should employ more sophisticated methodology to
screen forhypercoagulation state and, in the same time, clarify
if platelet activation occurs also in this setting; in this last
context, analysis of systemic markers of platelet activation
such as soluble P-selectin or IIb/IIIa could be useful to address
this issue. In the meantime, a hot issue is if SARS-CoV-2
patients should be treated or not with antithrombotic drugs
and if the clinical presentation may drive this therapeutic
decision (►Fig. 3). On the basis of previous reports showing
that patientswith pneumonia are associatedwith platelet and
clotting activation,3,4 interventional trials aimed at assessing
the efficacy of antithrombotic treatment, including aspirin or
low-molecular-weight heparin (LMWH), should be planned:
preliminary data suggested a potential efficacy of aspirin in
patients with pneumonia.30 Antithrombotic treatment could
be investigated in patients with severe pneumonia or pneu-
monia complicated by ARDS31 or by sepsis32 or needing
mechanical ventilation/ICU; the gray area is in case of no
pneumonia or pneumonia with low mortality risk according
to several risk scores such as PSI,33 CURB65,34 or SOFA,32 in
which antithrombotic treatment may be questionable; the
coexistence of elevate D-dimer in patientswithmild pneumo-
nia may be another setting to be investigated (►Fig. 3).
In absence of clinical trials and mechanism of disease
indicating the prominent role, if any, of platelets or clotting
system in favoring SARS-CoV-2 sequelae, treating all SARS-
CoV-2 with prophylactic doses of LMWH, independently
from clinical presentation and on the basis of laboratory
changes suggestive of a hypercoagulation state, may be
intriguing but premature until the interplay between hyper-
coagulation and SARS- CoV-2 is clarified35; previous study in
a different clinical setting, that is acutely ill medical patients,
demonstrated that without an appropriate definition of
hospitalized medical patients at risk of thrombosis, the
prophylaxis with LMWH is useless and potentially danger-
ous.36 Thus, patients with pneumonia, particularly those
with severe infections as defined by several scores and
suffering from complications as ARDS or sepsis or needing
mechanical ventilation/ICU treatment could be candidates to
Fig. 3 Suggested algorithm.
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randomized clinical trials with antithrombotic treatment
(►Fig. 3) to assess if this approach may blunt SARS-CoV-2
sequelae.
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